Opportunity Information: Apply for RFA CA 24 008
The Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) opportunity (RFA-CA-24-008) is a National Institutes of Health, National Cancer Institute (NCI) funding announcement aimed at early-stage, exploratory technology development. The central goal is to spark the creation of highly innovative tools that enable new ways to analyze cancer at the molecular and cellular levels. This is not a call for routine method optimization or incremental upgrades; it is geared toward technical leaps that can open up brand-new capabilities for targeting, probing, measuring, or otherwise characterizing fundamental features of cancer biology in research settings that may be basic or clinically oriented.
Projects that fit well are those developing technologies that improve how researchers can characterize cancer-related molecular and cellular features, with the expectation that these new capabilities could meaningfully accelerate progress across multiple cancer research and public health needs. The announcement explicitly connects the desired technology advances to downstream impact areas such as understanding cancer biology, improving early detection and screening approaches, strengthening clinical diagnosis, informing or monitoring treatment, supporting cancer control and epidemiology, and addressing challenges related to cancer health disparities. Technologies can be broadly applicable across cancer types or use cases, but they must remain clearly anchored in improving molecular and/or cellular characterization of cancer biology rather than general-purpose toolbuilding without a cancer-focused rationale.
This funding opportunity sits within the NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program, which is known for supporting novel measurement and analysis technologies that can transform what is feasible in cancer research. The mechanism specified is the R61, which is typically used for exploratory, early development activities where the emphasis is on establishing feasibility and demonstrating the core innovation. As the title notes, clinical trials are not allowed under this announcement, meaning applicants should not propose studies that meet NIH definitions of a clinical trial; the work should remain on technology development and validation consistent with preclinical, analytical, or non-trial clinical research contexts.
In terms of eligibility, the NOFO is broadly open across many organization types, reflecting an intent to attract innovation from academia, government, nonprofits, and industry. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized governments; nonprofits with or without 501(c)(3) status (outside higher education); for-profit organizations other than small businesses; and small businesses. The opportunity also highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations. This broad eligibility suggests NCI is seeking strong, unconventional technical ideas wherever they originate, including from communities and institutions positioned to contribute to equity-focused cancer research.
Key administrative details provided include the funding activity category (Education, Health), CFDA number 93.394, and the original application closing date of 2024-10-01. The listed award ceiling is $150,000. The synopsis does not specify the exact number of expected awards in the provided fields, indicating that applicants should consult the full NOFO text for any additional budget, project period, or award volume details not captured in the summary record. Overall, the program is best understood as a focused push to create next-generation molecular and cellular analysis technologies that can change what cancer researchers can measure, see, and interpret, ultimately enabling faster and more effective advances in understanding and addressing cancer.Apply for RFA CA 24 008
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2023-11-28.
- Applicants must submit their applications by 2024-10-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61; Clinical Trial Not Allowed) - RFA-CA-24-008
What is the purpose of this funding opportunity?
The opportunity supports early-stage, exploratory development of highly innovative molecular and cellular analysis technologies for cancer research. The aim is to spark technology breakthroughs that enable new ways to analyze cancer biology at molecular and cellular levels, rather than funding routine method optimization or incremental upgrades.
What agency is offering this grant?
This funding announcement is offered by the National Institutes of Health (NIH), specifically the National Cancer Institute (NCI).
What is the program this opportunity is associated with?
The announcement sits within the NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program, which supports novel measurement and analysis technologies intended to transform what is feasible in cancer research.
What grant mechanism is used for this opportunity?
The mechanism is an R61, which is typically used for exploratory, early development activities where the emphasis is on establishing feasibility and demonstrating the core innovation.
Are clinical trials allowed under this opportunity?
No. The announcement explicitly states "Clinical Trial Not Allowed." Applicants should not propose studies that meet the NIH definition of a clinical trial. The work should remain focused on technology development and validation consistent with preclinical, analytical, or non-trial clinical research contexts.
What kinds of projects are a good fit?
Projects are a good fit when they develop technologies that materially improve how researchers can characterize cancer-related molecular and cellular features. The emphasis is on technical leaps that open brand-new capabilities for targeting, probing, measuring, or otherwise characterizing fundamental features of cancer biology in basic or clinically oriented research settings.
What kinds of projects are not the focus of this announcement?
The opportunity is not aimed at routine method optimization or incremental upgrades. It is also not intended for general-purpose toolbuilding that lacks a clear cancer-focused rationale tied to molecular and/or cellular characterization of cancer biology.
Does the technology need to be tied to cancer specifically?
Yes. While the technology can be broadly applicable across cancer types or use cases, it must remain clearly anchored in improving molecular and/or cellular characterization of cancer biology, rather than being a generic platform without a cancer-focused justification.
What types of downstream impacts does NCI expect these technologies to enable?
The announcement connects desired technology advances to downstream impact areas including: understanding cancer biology, improving early detection and screening approaches, strengthening clinical diagnosis, informing or monitoring treatment, supporting cancer control and epidemiology, and helping address challenges related to cancer health disparities.
Is this opportunity intended for basic research, clinical research, or both?
It supports technology development relevant to both basic and clinically oriented cancer research settings, as long as the proposed studies do not qualify as clinical trials under NIH definitions.
Who is eligible to apply?
Eligibility is broad and includes many organization types across academia, government, nonprofits, and industry. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized governments; nonprofits with or without 501(c)(3) status (outside higher education); for-profit organizations other than small businesses; and small businesses.
Are non-U.S. (foreign) organizations eligible?
Yes. The eligibility list explicitly includes non-U.S. (foreign) organizations.
Are U.S. territories or possessions eligible?
Yes. The opportunity highlights eligibility for U.S. territories or possessions.
Are minority-serving institutions specifically included as eligible applicants?
Yes. The opportunity highlights additional eligible groups including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly listed among the additional eligible groups.
Are federal agencies eligible to apply?
Yes. The opportunity lists eligible federal agencies among the additional eligible groups.
What is the CFDA number for this opportunity?
The CFDA number provided is 93.394.
What is the funding activity category?
The funding activity category is listed as Education and Health.
What is the application due date listed in the synopsis?
The original application closing date provided is 2024-10-01.
What is the maximum award amount (award ceiling) listed?
The listed award ceiling is $150,000.
How many awards will be made?
The synopsis does not specify the number of expected awards in the provided fields. Applicants are expected to consult the full NOFO for details that may not be included in the summary record.
Does the synopsis provide full budget and project period details?
Not in the information provided here. The synopsis notes that some details (such as budget specifics, project period, or award volume) may require consulting the full NOFO text.
What is the central theme of the technologies being sought?
The central theme is enabling new molecular and cellular analysis capabilities for cancer research: tools that change what researchers can measure, see, and interpret about cancer biology, and that can accelerate progress across multiple cancer research and public health needs.
Browse more opportunities from the same category: Education, Health
Next opportunity: Advancing Learning Health Care Research in Outpatient Mental Health Treatment Settings (R34 Clinical Trial Optional)
Previous opportunity: 2024 Alaska Native Organization Co-Management Funding Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 24 008
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 24 008) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional) Apply for RFA CA 24 015 Funding Number: RFA CA 24 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) Apply for RFA CA 24 014 Funding Number: RFA CA 24 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 24 011 Funding Number: RFA CA 24 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Apply for RFA CA 24 013 Funding Number: RFA CA 24 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) Apply for RFA CA 24 012 Funding Number: RFA CA 24 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 24 009 Funding Number: RFA CA 24 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Providing Research Education Experiences to Enhance Inclusivity for a Diverse Substance Use and Addiction Scientific Workforce (R25 Clinical Trials Not Allowed) Apply for PAR 24 048 Funding Number: PAR 24 048 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional) Apply for PAR 24 077 Funding Number: PAR 24 077 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) Apply for RFA CA 24 021 Funding Number: RFA CA 24 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: $900,000 |
| Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 009 Funding Number: RFA DA 25 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed) Apply for RFA DA 25 010 Funding Number: RFA DA 25 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 023 Funding Number: RFA DA 25 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Assessment of Climate at Institutions (ACt) Award (RC2 - Clinical Trial Not Allowed) Apply for PAR 24 038 Funding Number: PAR 24 038 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) Apply for PAR 24 088 Funding Number: PAR 24 088 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) Apply for RFA CA 24 016 Funding Number: RFA CA 24 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Apply for RFA CA 24 018 Funding Number: RFA CA 24 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) Apply for RFA CA 24 017 Funding Number: RFA CA 24 017 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Apply for RFA CA 24 019 Funding Number: RFA CA 24 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) Apply for PAR 24 085 Funding Number: PAR 24 085 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) Apply for PAR 24 072 Funding Number: PAR 24 072 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 24 008", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.